Matrix M Adjuvanted H5N1 Vaccine Elicits Broadly Neutralizing Antibodies and Neuraminidase Inhibiting Antibodies in Humans That Correlate With In Vivo Protection

Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial

(2021) Mehreen S Datoo et al.   LANCET

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

(2021) Paul T. Heath et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

(2020) Cheryl Keech et al.   NEW ENGLAND JOURNAL OF MEDICINE

NGPhylogeny.fr: new generation phylogenetic services for non-specialists

(2019) Frédéric Lemoine et al.   NUCLEIC ACIDS RESEARCH

Functional Immune Response to Influenza H1N1 in Children and Adults after Live Attenuated Influenza Virus Vaccination

(2019) Shahinul Islam et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

Prolonged evolution of the memory B cell response induced by a replicating adenovirus-influenza H5 vaccine

(2019) Kenta Matsuda et al.   Science Immunology

Emerging from the Shadow of Hemagglutinin: Neuraminidase Is an Important Target for Influenza Vaccination

(2019) Florian Krammer et al.   Cell Host & Microbe

Meeting report and review: Immunological assays and correlates of protection for next‐generation influenza vaccines

(2019) Florian Krammer et al.   Influenza and Other Respiratory Viruses

Selective induction of antibody effector functional responses using MF59-adjuvanted vaccination

(2019) Carolyn M. Boudreau et al.   JOURNAL OF CLINICAL INVESTIGATION

Neuraminidase as an influenza vaccine antigen: a low hanging fruit, ready for picking to improve vaccine effectiveness

(2018) Maryna C Eichelberger et al.   CURRENT OPINION IN IMMUNOLOGY

The influenza virus hemagglutinin head evolves faster than the stalk domain

(2018) Ericka Kirkpatrick et al.   Scientific Reports

A DNA Vaccine That Targets Hemagglutinin to Antigen-Presenting Cells Protects Mice against H7 Influenza

(2017) Tor Kristian Andersen et al.   JOURNAL OF VIROLOGY

Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M™

(2017) Navin Venkatraman et al.   VACCINE

Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for In Vivo Protection in a Serum Transfer Mouse Challenge Model

(2017) Henning Jacobsen et al.   mBio

Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection

(2016) David J. DiLillo et al.   JOURNAL OF CLINICAL INVESTIGATION

Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model

(2016) Matthew J. Memoli et al.   mBio

Dissecting the hemagglutinin head and stalk-specific IgG antibody response in healthcare workers following pandemic H1N1 vaccination

(2016) Sarah M Tete et al.   npj Vaccines

Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection

(2015) Arnold S. Monto et al.   JOURNAL OF INFECTIOUS DISEASES

Matrix M H5N1 Vaccine Induces Cross-H5 Clade Humoral Immune Responses in a Randomized Clinical Trial and Provides Protection from Highly Pathogenic Influenza Challenge in Ferrets

(2015) Rebecca J. Cox et al.   PLoS One

A Live Attenuated Influenza A(H5N1) Vaccine Induces Long-Term Immunity in the Absence of a Primary Antibody Response

(2014) Kawsar R. Talaat et al.   JOURNAL OF INFECTIOUS DISEASES

Induction of Broadly Reactive Anti-Hemagglutinin Stalk Antibodies by an H5N1 Vaccine in Humans

(2014) R. Nachbagauer et al.   JOURNAL OF VIROLOGY

Broadly neutralizing hemagglutinin stalk–specific antibodies require FcγR interactions for protection against influenza virus in vivo

(2014) David J DiLillo et al.   NATURE MEDICINE

Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans

(2014) A. H. Ellebedy et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Matrix MTMadjuvanted virosomal H5N1 vaccine induces balanced Th1/Th2 CD4+T cell responses in man

(2014) Gabriel K Pedersen et al.   Human Vaccines & Immunotherapeutics

Antibody Correlates and Predictors of Immunity to Naturally Occurring Influenza in Humans and the Importance of Antibody to the Neuraminidase

(2013) Robert B. Couch et al.   JOURNAL OF INFECTIOUS DISEASES

H5N1 vaccines in humans

(2013) Mariana Baz et al.   VIRUS RESEARCH

A Triclade DNA Vaccine Designed on the Basis of a Comprehensive Serologic Study Elicits Neutralizing Antibody Responses against All Clades and Subclades of Highly Pathogenic Avian Influenza H5N1 Viruses

(2012) F. Zhou et al.   JOURNAL OF VIROLOGY

ISCOM technology-based Matrix M™ adjuvant: success in future vaccines relies on formulation

(2011) Karin Lövgren Bengtsson et al.   Expert Review of Vaccines

Safety and Immunogenicity of Influenza A H5 Subunit Vaccines: Effect of Vaccine Schedule and Antigenic Variant

(2011) Robert B. Belshe et al.   JOURNAL OF INFECTIOUS DISEASES

Hemagglutination Inhibition Antibody Titers as a Correlate of Protection for Inactivated Influenza Vaccines in Children

(2011) Steven Black et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial

(2011) Rebecca J. Cox et al.   VACCINE

Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses

(2009) Isabella Alberini et al.   VACCINE

Measurement of neutralizing antibody responses against H5N1 clades in immunized mice and ferrets using pseudotypes expressing influenza hemagglutinin and neuraminidase

(2009) Cheguo Tsai et al.   VACCINE

Update on Avian Influenza A (H5N1) Virus Infection in Humans

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Phylogeny.fr: robust phylogenetic analysis for the non-specialist

(2008) A. Dereeper et al.   NUCLEIC ACIDS RESEARCH

Broad Clade 2 Cross-Reactive Immunity Induced by an Adjuvanted Clade 1 rH5N1 Pandemic Influenza Vaccine

(2008) Isabel Leroux-Roels et al.   PLoS One

Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults

(2008) Terry M. Nolan et al.   VACCINE

Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children

(2008) Terry Nolan et al.   VACCINE